Multiply Labs Scaling Robotics in Cell Therapy Biomanufacturing
Multiply Labs: Automating Cell Therapy Manufacturing
Table of Contents
Multiply Labs is automating cell therapy manufacturing using robotics,aiming to reduce costs,increase speed,and improve precision compared to traditional manual processes. The company’s approach mirrors advancements seen in the semiconductor industry, where automation dramatically improved efficiency.
The Problem with Traditional Cell Therapy Production
Cell therapy manufacturing is currently a largely manual, labor-intensive, and expensive process. Maintaining sterility and precision are critical, but challenging, with human operators. This limits scalability and accessibility of these possibly life-saving treatments.
According to a 2023 report by the U.S.Food and Drug Administration, significant challenges remain in scaling up cell therapy manufacturing to meet growing demand, with cost and complexity being key hurdles.
Multiply labs’ Robotic Solution
Multiply Labs develops robotic systems designed to perform the repetitive and precise tasks involved in cell therapy production. These robots are intended to operate within controlled environments, minimizing contamination risks and ensuring consistent product quality. The company’s initial concept originated from PhD research conducted by Fred parietti at MIT.
In a TechCrunch article from October 26, 2023, Multiply Labs announced a $75 million funding round to accelerate the advancement and deployment of its robotic manufacturing platform.
Key Features and Benefits
The core benefit of Multiply Labs’ technology is increased efficiency and reduced costs. By automating key steps, the company aims to lower the cost of goods sold (COGS) for cell therapies, making them more accessible to patients.Automation also promises to improve consistency and reduce the risk of human error.
- Reduced Costs: Automation lowers labor costs and minimizes material waste.
- Increased Speed: Robots can operate continuously, accelerating production timelines.
- Improved Quality: Precise robotic movements and controlled environments enhance product consistency.
According to a company statement on their website, their system is designed to handle multiple cell therapy modalities, offering flexibility for different treatment types.
Company Background and Funding
Multiply Labs was founded by Fred Parietti, who previously conducted research at MIT’s Koch Institute for Integrative Cancer research. The company has attracted significant investment from venture capital firms focused on biotechnology and automation.
The $75 million Series B funding round, led by General Catalyst and OrbiMed, will be used to expand the company’s manufacturing capacity and accelerate the commercialization of its platform. This details was reported by Fierce Biotech on October 26,2023.
Breaking News Check (as of 2026/01/15 05:21:09)
As of January 15, 2026, a search of authoritative news sources (including fierce Biotech, TechCrunch,and GEN Engineering News) reveals no significant new developments regarding Multiply Labs beyond the October 2023 funding proclamation.The company continues to operate and develop its automated cell therapy manufacturing platform. Recent press releases on the Multiply Labs News page indicate ongoing partnerships and platform refinement, but no major shifts in strategy or funding.